Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation-Reference-Cited by-同舟云学术

Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation

Published:2020-11 Issue:S1 Volume:60 Page:
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Franchetti Yoko¹,Nolin Thomas D.²^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, Center for Clinical Pharmaceutical Sciences University of Pittsburgh School of Pharmacy Pittsburgh Pennsylvania USA

2. Department of Pharmacy and Therapeutics Center for Clinical Pharmaceutical Sciences University of Pittsburgh School of Pharmacy Pittsburgh Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1741

Reference110 articles.

1. Centers for Disease Control and Prevention.Chronic Kidney Disease in the United States 2019.https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html. Published2019. Accessed January 7 2020.

2. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (NIDDK). Kidney Disease Statistics for the United States.https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Published2016. Accessed January 7 2020.

3. Emerging Evidence of the Impact of Kidney Disease on Drug Metabolism and Transport

4. Pharmacometric modeling and simulation is essential to pediatric clinical pharmacology;Neely M;J Clin Pharmacol,2018

5. Early research on renal function and drug action;Reidenberg MM;J Clin Pharmacol,2012

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations;Xenobiotica;2024-02-21

2. A Comprehensive Physiologically Based Pharmacokinetic Model of Nadolol in Adults with Renal Disease and Pediatrics with Supraventricular Tachycardia;Pharmaceuticals;2024-02-19

3. Physiologically Based Pharmacokinetic Model To Predict Metoprolol Disposition in Healthy and Disease Populations;ACS Omega;2023-08-03

4. A physiologically based pharmacokinetic model of cefepime to predict its pharmacokinetics in healthy, pediatric and disease populations;Saudi Pharmaceutical Journal;2023-08

5. Predicting the Effect of Renal Function on Systemic Clearance: Is a Simple Scaling Method Sufficient?;Journal of Pharmaceutical Sciences;2023-06